Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.72 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.70 -0.02 (-1.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 1 - 20 ( 312 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Fortress Raises $10M w/Participation by Directors/Officers. Adjusting for Dilution we Lower Our Price Target from $12 to $10.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Reverse Stock Split 1:15, Price Target Set to $12.0
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Updated Model - Monetizations Could Restart in 2024
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: The Hits Just Keep CominÂ’ Checkpoint Releases Promising Data in Advanced Cutaneous Cell Carcinoma
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Avenue Therapeutics (ATXI), A Fortress Company, Announces Agreement with the FDA
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Journey Medical - Positive Pivotal Data
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J